Biomedicines · 8 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review synthesizes knowledge on the shared molecular pathways, such as inflammation and oxidative stress, linking cardiovascular diseases (CVD) and diabetes mellitus (DM). It highlights that drugs like SGLT-2 inhibitors and GLP-1 receptor agonists show a beneficial dual effect on both conditions.
It identifies inflammation, oxidative stress, and advanced glycation end products as key shared pathological processes. The review also discusses the role of the gut microbiota in influencing both conditions. A central focus is on treatments, particularly sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which are noted for their positive impact on both CVD and DM, a benefit attributed to the interdependence of disease pathogenesis. The implication is that a holistic treatment approach targeting common pathways is beneficial and that future drug research should focus on these shared mechanisms.
